Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
Checked against the public recordLast updated Oct 23, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Dana-Farber Cancer Institute
- Interventions being studied
- Radiation: Whole brain radiation; Radiation: Stereotactic radiation (SRS)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. Patients who have undergone prior systemic therapy are eligible * Five-twenty intracranial lesions must be present on MRI of the brain * Age 18-80 years at diagnosis of brain metastases * Karnofsky performance status of at least 70 Exclusion Criteria: * Participants who have undergone prior radiation for brain metastases. * Patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study * Participants who cannot undergo a brain MRI * Participants who cannot receive gadolinium (MRI contrast) * Participants with stage IV-V chronic kidney disease or end stage renal disease * Participants with widespread, definitive leptomeningeal disease * Participants with small cell lung cancer, lymphoma, or myeloma * Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brigham and Women's HospitalBoston, Massachusetts
- Dana Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 23, 2024. Always confirm current availability with the study team.